956907-50-9

Upstream product

• 98-16-8 3-trifluoromethylaniline 
• 17738-86-2 ethyl 2-oxo-2-((3-(trifluoromethyl)phenyl)amino)acetate 
• 433241-66-8 N-(2-hydroxypropyl)-N'-[3-(trifluoromethyl)-phenyl]ethanediamide 
• 956907-63-4 N-(2-oxopropyl)-N'-[3-(trifluoromethyl)-phenyl]ethanediamide 
• 956907-67-8 6-methyl-1-[3-(trifluoromethyl)phenyl]-1,4-dihydropyrazine-2,3-dione 
• 956907-59-8 3-bromo-6-methyl-1-[3-(trifluoromethyl)phenyl]pyrazin-2(1H)-one 
• 956907-37-2 5-Methyl-3-oxo-4-(3-trifluoromethyl-phenyl)-3,4-dihydro-pyrazine-2-carboxylic acid methyl ester 

Downstream Products

• 1148547-36-7 6-(2-chloro-pyridin-3-yl)-5-methyl-3-oxo-4-(3-trifluoromethyl-phenyl)-3,4-dihydro-pyrazine-2-carboxylic acid methyl ester 
• 1150620-55-5 methyl 6-[2-(4-chlorophenyl)pyrazol-3-yl]-5-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-3,4-dihydropyrazine-2-carboxylate 

Relevant academic research and scientific papers

SOME 2-PYRAZINONE DERIVATIVES AND THEIR USE AS INHIBITORS OF NEUTROPHILE ELASTASE

The invention provides certain novel 6-heteroaryl-5-methyl-3- oxo-4- [3 (trif luoromethyl) phenyl] -3,4-dihydropyrazine-2- carboxamide derivatives and pharmaceutically acceptable salts thereof and particular Forms thereof; together with processes for thei

2-PYRAZINONE DERIVATIVES AND THEIR USE AS INHIBITORS OF NEUTROPHILE ELASTASE

The invention provides compounds of formula (I) wherein R1, R3, R4, R5, R14, X and W are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceut

2-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY IS BENEFICIAL.

The invention provides compounds of formula (I) wherein R1, R3, R4, R5, R14, X and W are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acce